Biologics CDMO Market Size to Grow by USD 8.65 Billion, Availability of Cost-efficient Resources in Emerging Markets to Boost Growth - Technavio

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- The global biologics CDMO market size is set to grow by USD 8.65 billion from 2021 to 2026, according to Technavio. Moreover, the growth momentum of the market is expected to accelerate at a CAGR of 12.20% during the forecast period. Use our report analysis and insights for effective decision making. Download a FREE Sample Report

Key Market Drivers

The growth of the biologics CDMO market is attributed to factors such as the availability of cost-efficient resources in emerging markets. For instance, India is one of the most preferred countries for CDMOs. The country has more than 100 US FDA-approved manufacturing facilities, and the number of such facilities is growing. Companies such as LUPIN and Zydus Cadila have a strong presence in the country, which is increasing the share of the biologics CDMO market. India accounts for an estimated one-third of the revenue of the global biologics CDMO market.

Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. Buy Now for detailed information about market dynamics

Biologics CDMO Market Type Outlook (Revenue, USD bn, 2021-2026)

• Mammalian - size and forecast 2021-2026
• Microbial - size and forecast 2021-2026
• Cell therapy services - size and forecast 2021-2026

Biologics CDMO Market Geography Outlook (Revenue, USD bn, 2021-2026)

• North America - size and forecast 2021-2026
• Europe - size and forecast 2021-2026
• Asia - size and forecast 2021-2026
• ROW - size and forecast 2021-2026

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View an Exclusive FREE Sample Report

Market Segmentation

The mammalian segment will be a significant contributor to market growth during the forecast period. Mammalian cell culture is the process of growing animal cells in vitro in a flask or dish. There are four types of mammalian cells, namely epithelial cells, fibroblasts, lymphocytes, and macrophages. Human proteins with high therapeutic potential, such as clotting factors, tissue plasminogen activators, and erythropoietin, are produced with mammalian cell culture. Recombinant proteins from mammalian cells are used in therapeutics for various diseases, ranging from diabetes to cancer. Mammalian cell culture technology is one of the well-established technologies for the production of vaccines in bulk. Hence, the use of this technology by biopharmaceutical companies for bulk vaccine production is supporting revenue generation in this market segment.

North America will account for 41% of the market's growth during the forecast period. This growth is attributed to factors such as rising patient awareness about the benefits of the use of biologics. Moreover, market growth in this region will be faster than the growth of the market in ROW. The US and Canada are the key countries for the biologics CDMO market in North America.

Major Biologics CDMO Companies

• AGC Biologics
• Binex Co. Ltd.
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Fujifilm Diosynth Biotechnologies USA Inc.
• JRS PHARMA GmbH and Co. KG
• Lonza Group Ltd.
• Rentschler Biopharma SE
• Samsung BioLogics Co. Ltd.
• WuXi Biologics (Cayman) Inc.

Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000

Related Reports

Cancer Biologics Market by Product and Geography - Forecast and Analysis 2022-2026: The cancer biologics market share is expected to increase by USD 34.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.91%. This report extensively covers segmentation by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Plasma Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026: The plasma therapeutics market share is expected to increase by USD 8.98 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.1%. This report extensively covers segmentation by product (immunoglobulin, albumin, blood factors, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Browse Health Care Market Reports

Table of Contents

1. Executive Summary                         

               1.1 Market Overview 

2. Market Landscape                            

               2.1 Market ecosystem             

                              2.1.1 Parent market

                              Exhibit 01:  Parent market

                              Exhibit 02:  Market characteristics

               2.2 Value chain analysis           

                              Exhibit 03: Value chain analysis: Pharmaceuticals

                              2.2.1 Research and development (R&D) and drug discovery

                              2.2.2 Integration and product development

                              2.2.3 Manufacturing

                              2.2.4 Outbound logistics

                              2.2.5 Marketing and sales

                              2.2.6 Support services

3. Market Sizing                      

               3.1 Market segment analysis  

                              Exhibit 04:  Market segments

               3.2 Market size 2021 

               3.3 Market definition

                              Exhibit 05:  Offerings of vendors included in the market definition

               3.4 Market outlook: Forecast for 2021 - 2026 

                              3.4.1 Estimating growth rates for emerging and high-growth markets

                              3.4.2 Estimating growth rates for mature markets

                              Exhibit 06:  Global - Market size and forecast 2021 - 2026 ($ million)

                              Exhibit 07:  Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis                         

               4.1 Five Forces Summary         

                              Exhibit 08:  Five forces analysis 2021 & 2026

               4.2 Bargaining power of buyers            

                              Exhibit 09: Bargaining power of buyers

               4.3 Bargaining power of suppliers        

                              Exhibit 10: Bargaining power of suppliers

               4.4 Threat of new entrants     

                              Exhibit 11: Threat of new entrants

               4.5 Threat of substitutes          

                              Exhibit 12: Threat of substitutes

               4.6 Threat of rivalry   

                              Exhibit 13: Threat of rivalry

               4.7 Market condition 

                              Exhibit 14:  Market condition - Five forces 2021

5. Market Segmentation by Type                    

               5.1 Market segments

                              Exhibit 15:  Type - Market share 2021-2026 (%)

               5.2 Comparison by Type          

                              Exhibit 16:  Comparison by Type

               5.3 Mammalian - Market size and forecast 2021-2026

                              Exhibit 17:  Mammalian - Market size and forecast 2021-2026 ($ million)

                              Exhibit 18:  Mammalian - Year-over-year growth 2021-2026 (%)

               5.4 Microbial - Market size and forecast 2021-2026     

                              Exhibit 19:  Microbial - Market size and forecast 2021-2026 ($ million)

                              Exhibit 20:  Microbial - Year-over-year growth 2021-2026 (%)

               5.5 Cell therapy services - Market size and forecast 2021-2026              

                              Exhibit 21:  Cell therapy services - Market size and forecast 2021-2026 ($ million)

                              Exhibit 22:  Cell therapy services - Year-over-year growth 2021-2026 (%)

               5.6 Market opportunity by Type          

                              Exhibit 23:  Market opportunity by Type

6. Customer landscape                        

                               Exhibit 24: Customer landscape

7. Geographic Landscape                    

               7.1 Geographic segmentation

                              Exhibit 25:  Market share by geography 2021-2026 (%)

               7.2 Geographic comparison    

                              Exhibit 26: Geographic comparison

               7.3 North America - Market size and forecast 2021-2026          

                              Exhibit 27:  North America - Market size and forecast 2021-2026 ($ million)

                              Exhibit 28:  North America - Year-over-year growth 2021-2026 (%)

               7.4 Europe - Market size and forecast 2021-2026         

                              Exhibit 29:   Europe - Market size and forecast 2021-2026 ($ million)

                              Exhibit 30:  Europe - Year-over-year growth 2021-2026 (%)

               7.5 Asia - Market size and forecast 2021-2026

                              Exhibit 31:   Asia - Market size and forecast 2021-2026 ($ million)

                              Exhibit 32:  Asia - Year-over-year growth 2021-2026 (%)

               7.6 ROW - Market size and forecast 2021-2026             

                              Exhibit 33:   ROW - Market size and forecast 2021-2026 ($ million)

                              Exhibit 34:  ROW - Year-over-year growth 2021-2026 (%)

               7.7 Key leading countries        

                              Exhibit 35:  Key leading countries

               7.8 Market opportunity by geography

                              Exhibit 36: Market opportunity by geography

8. Drivers, Challenges, and Trends                  

               8.1 Market drivers      

                              8.1.1 Availability of cost-efficient resources in emerging markets

                              8.1.2 Strong research and development pipeline of biologics therapeutics

                              8.1.3 Growing need to focus on core competencies

               8.2 Market challenges              

                              8.2.1 Capacity utilization and constraints

                              8.2.2 Stringent policies related to entry of new biologics

                              8.2.3 Stereotypical nature of CDMOs

                              Exhibit 37:  Impact of drivers and challenges

               8.3 Market trends      

                              8.3.1 Advent of big data

                              8.3.2 Strategic alliances and partnerships with pharma companies

                              8.3.3 Increasing approvals for new molecules and biosimilars?

9. Vendor Landscape                            

               9.1 Vendor landscape

                              Exhibit 38: Vendor landscape

                              The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025. 

               9.2 Landscape disruption         

                              Exhibit 39: ?Landscape disruption?

                              Exhibit 40: Industry risks

10. Vendor Analysis               

               10.1 Vendors covered              

                              Exhibit 41: Vendors covered

               10.2 Market positioning of vendors    

                              Exhibit 42: ?Market positioning of vendors?

               10.3 AGC Biologics     

                              Exhibit 43:  AGC Biologics - Overview

                              Exhibit 44:  AGC Biologics - Product and service

                              Exhibit 45:  AGC Biologics - Key offerings

               10.4 Binex Co. Ltd.

                              Exhibit 46:  Binex Co. Ltd. - Overview

                              Exhibit 47:  Binex Co. Ltd. - Product and service

                              Exhibit 48:  Binex Co. Ltd. - Key offerings

               10.5 Boehringer Ingelheim International GmbH            

                              Exhibit 49:  Boehringer Ingelheim International GmbH - Overview

                              Exhibit 50:  Boehringer Ingelheim International GmbH - Business segments

                              Exhibit 51:  Boehringer Ingelheim International GmbH - Key offerings

                              Exhibit 52:  Boehringer Ingelheim International GmbH - Segment focus

               10.6 Catalent Inc.       

                              Exhibit 53:  Catalent Inc. - Overview

                              Exhibit 54:  Catalent Inc. - Business segments

                              Exhibit 55:  Catalent Inc. - Key offerings

                              Exhibit 56:  Catalent Inc. - Segment focus

               10.7 Fujifilm Diosynth Biotechnologies USA Inc.            

                              Exhibit 57:  Fujifilm Diosynth Biotechnologies USA Inc. - Overview

                              Exhibit 58:  Fujifilm Diosynth Biotechnologies USA Inc. - Product and service

                              Exhibit 59:  Fujifilm Diosynth Biotechnologies USA Inc. - Key offerings

               10.8 JRS PHARMA GmbH and Co. KG  

                              Exhibit 60:  JRS PHARMA GmbH and Co. KG - Overview

                              Exhibit 61:  JRS PHARMA GmbH and Co. KG - Product and service

                              Exhibit 62:  JRS PHARMA GmbH and Co. KG - Key offerings

               10.9 Lonza Group Ltd.              

                              Exhibit 63:  Lonza Group Ltd. - Overview

                              Exhibit 64:  Lonza Group Ltd. - Business segments

                              Exhibit 65:  Lonza Group Ltd. - Key offerings

                              Exhibit 66:  Lonza Group Ltd. - Segment focus

               10.10 Rentschler Biopharma SE           

                              Exhibit 67:  Rentschler Biopharma SE - Overview

                              Exhibit 68:  Rentschler Biopharma SE - Product and service

                              Exhibit 69:  Rentschler Biopharma SE - Key offerings

               10.11 Samsung BioLogics Co. Ltd.        

                              Exhibit 70:  Samsung BioLogics Co. Ltd. - Overview

                              Exhibit 71:  Samsung BioLogics Co. Ltd. - Business segments

                              Exhibit 72:  Samsung BioLogics Co. Ltd. - Key offerings

               10.12 WuXi Biologics (Cayman) Inc.    

                              Exhibit 73:  WuXi Biologics (Cayman) Inc. - Overview

                              Exhibit 74:  WuXi Biologics (Cayman) Inc. - Business segments

                              Exhibit 75:  WuXi Biologics (Cayman) Inc. - Key offerings

                              Exhibit 76:  WuXi Biologics (Cayman) Inc. - Segment focus

11. Appendix                           

               11.1 Scope of the report         

                              11.1.1 Market definition

                              11.1.2 Objectives

                              11.1.3 Notes and Caveats

               11.2 Currency conversion rates for US$            

                              Exhibit 77: Currency conversion rates for US$

               11.3 Research Methodology   

                              Exhibit 78: Research Methodology

                              Exhibit 79: Validation techniques employed for market sizing

                              Exhibit 80: Information sources

               11.4 List of abbreviations        

                              Exhibit 81: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Newsroom: https://newsroom.technavio.org/news/biologics-cdmomarket

SOURCE Technavio